These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38374435)

  • 1. Tabelecleucel is effective in EBV-positive lymphoproliferative disease.
    Romero D
    Nat Rev Clin Oncol; 2024 Apr; 21(4):251. PubMed ID: 38374435
    [No Abstract]   [Full Text] [Related]  

  • 2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
    Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tabelecleucel: First Approval.
    Keam SJ
    Mol Diagn Ther; 2023 May; 27(3):425-431. PubMed ID: 37016096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The cutting-edge of medicine; Epstein-Barr virus associated lymphoproliferative disorders: disease concept and treatment].
    Suzuki R
    Nihon Naika Gakkai Zasshi; 2013 Apr; 102(4):979-85. PubMed ID: 23772516
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic Epstein-Barr Virus-positive T-Cell Lymphoproliferative Disease of Childhood With Good Response to Steroid Therapy.
    Kim DH; Kim M; Kim Y; Han K; Han E; Lee JW; Chung NG; Cho B
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):e497-e500. PubMed ID: 28697169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
    Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
    Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-associated hydroa vacciniforme-like lymphoproliferative syndrome: excellent response to antiviral therapy.
    İmren IG; Demirkan N; Çomut E; Duygulu Ş
    Int J Dermatol; 2020 Dec; 59(12):e452-e454. PubMed ID: 32808321
    [No Abstract]   [Full Text] [Related]  

  • 8. Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
    Mwanda WO; Whalen C; Remick SC
    East Afr Med J; 2005 Sep; 82(9 Suppl):S133-4. PubMed ID: 16619688
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
    Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
    Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV
    Chaganti S; Barlev A; Caillard S; Choquet S; Cwynarski K; Friedetzky A; González-Barca E; Sadetsky N; Schneeberger S; Thirumalai D; Zinzani PL; Trappe RU
    Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus reactivation influences clonal evolution in human herpesvirus-8-related lymphoproliferative disorders.
    Granai M; Facchetti M; Mancini V; Goedhals J; Sherriff A; Mundo L; Bellan C; Amato T; Sorrentino E; Ungari M; Raphael M; Leoncini L; Facchetti F; Lazzi S
    Histopathology; 2021 Dec; 79(6):1099-1107. PubMed ID: 34431125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies for posttransplant lymphoproliferative disorder.
    Perkins JD
    Liver Transpl; 2006 Jun; 12(6):1013-4. PubMed ID: 16823952
    [No Abstract]   [Full Text] [Related]  

  • 18. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
    Toner K; Bollard CM
    Blood; 2022 Feb; 139(7):983-994. PubMed ID: 34437680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant Epstein-Barr virus-driven CD8 positive T-cell lymphoproliferative disorder with chromosomal abnormality.
    Tanoshima R; Goto H; Kato H; Yokosuka T; Kajiwara R; Yokota S
    Pediatr Blood Cancer; 2011 Jul; 57(1):182. PubMed ID: 21445947
    [No Abstract]   [Full Text] [Related]  

  • 20. Aggressive Tongue Root Epstein-Barr Virus-Positive Mucocutaneous Ulcer Treated With Rituximab Alone.
    Tsutsumi M; Yoshimura T; Tatsumi N; Nakaya Y; Fuseya H; Horiuchi M; Yoshida M; Hayashi Y; Nakao T; Inoue T; Yamane T
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e291-e294. PubMed ID: 32179033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.